Secondary Objectives

- To evaluate the PK and PD of single-agent X4P-001 and in combination with axitinib in healthy volunteers.

- To evaluate the PK and PD of single-agent X4P-001 and in combination with axitinib in ccRCC patients.

- To evaluate the safety, tolerability, and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To explore the PK and PD of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinib in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the safety and tolerability of X4P-001 in combination with axitinab in ccRCC patients.

- To evaluate the efficacy and safety of X4P-001 in combination with axitinab in ccRCC patients.